Legend Biotech shareholders voted at annual general meeting
LEGN•Legend Biotech shareholders held their annual general meeting on Sept. 24, 2026, approving an amendment to add 19.1 million ordinary shares to the share plan and re-electing four directors.
1. Meeting approvals
Shareholders received the audited consolidated financial statements for the year ended Dec. 31, 2025, and ratified Ernst & Young LLP as independent auditor for the fiscal year ending Dec. 31, 2026. Robin Meng, Corazon D. Sanders, Li Mao and Peter Salovey were re-elected as Class III directors for three-year terms. Shareholders also adopted a share plan amendment adding 19.1 million ordinary shares and authorized directors and officers to implement the resolutions.
